Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-1611015

  • Global Hyperphosphatemia Drugs Market Insights, Opportunities, Analysis, Market Shares and Forecast 2017 – 2023

  • Publish: May 2016 | Report Code: HPH-1611015

* For discount/customization and buying a particular chapter click here or write to us at [email protected]

Hypophosphatemia predicted in patients who have an antiquity of starvation, anorexia/bulimia, alcoholism. Adequate cure comprises phosphate supplements along with feeding and care to causal eating disorders or substance exploitation. The global hypophosphatemia drugs market is driven by increasing aging population. According to WHO the world aged population by the end of 2050 is expected to reach 2 billion that is 900 million in 2015. Now Around 125 million people aged 80 years or more. By the end of 2050 almost 125 million people aged 80 years or more is expected to reach in China alone and 434 million people across the globe. Approximately 80% people live in low and middle income countries by the end of 2050. As the increasing aging population is one of the major driving factor of global hypophosphatemia drugs market.

The global Hypophosphatemia drugs market is estimated to see new heights during the forecasted period. The stringent government regulations and presence of alternatives are hampering the growth of Hypophosphatemia drugs in the global market. The untapped APAC region is creating the huge opportunities for the forecasted period in global Hypophosphatemia drugs market.

The Hypophosphatemia drugs is segmented on the basis of application, medical care and geography. The application segment is segmented into mineral supplements, vitamin D preparation and calcimimetic drugs. Medical care segment is further segmented into cause, severity and duration.

The global Hypophosphatemia drugs market is driven by the presence of some the prominent player in the market. Biotech Pharmacal, Cipla, DM Pharma, DSM, Johnson & Jhonson, Pfizer, Sun Pharm Inc. and UltraGenyx. The mergers, acquisition, innovation, product development are the key strategies adopted by key players to sustain into competitive market. may 11, 2016, Johnson & Johnson opens JLABS in Torronto, in which they are providing offoces, modular labs, access to industry capital funding. In this JLABS facility provide accommodations 50 startups and opens with 22 companies dealing in various sector in healthcare drug innovation.

On the basis of geography North America, Europe, Asia Pacific and RoW are the major segments. The Asia Pacific dominates the Hypophosphatemia drugs market with holding the largest market share.  The large share is dominated by increasing aging population in the region. The rising osteoporosis in the APAC region is also driving the growth in the APAC market. the North America is the fastest growing region in the global market. the growth is majorly driven by the changing dietary habits in the region and increasing osteoporosis in the North America region.

CHAP# 1.             INTRODUCTION

# 1.1.     EXECUTIVE SUMMARY

# 1.2.     ESTIMATION METHODOLOGY

CHAP# 2.             MARKET OVERVIEW

# 2.1.     MARKET DEFINITION AND SCOPE

# 2.2.     KEY FINDINGS

# 2.3.     PARAMETRIC ANALYSIS

# 2.3.1. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE

# 2.3.2. GROWING HEALTH CARE EXPENDITURE ACROSS GEOGRAPHIES

# 2.3.3. RISE IN MEDICAL TOURISM

# 2.4.     KEY MARKET INSIGHTS

# 2.4.1. TOP 3 EMERGING COUNTRIES

# 2.4.2. TOP REVENUE GENERATING SEGMENTS

# 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS

# 2.5.     COMPETITIVE LANDSCAPE

# 2.5.1. MARKET SHARE ANALYSIS

# 2.5.2. TOP WINNING STRATEGIES

# 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES

# 2.6.     PORTER’S FIVE FORCE MODEL

# 2.6.1. THREAT OF NEW ENTRANTS

# 2.6.2. BARGAINING POWER OF BUYERS

# 2.6.3. BARGAINING POWER OF SUPPLIERS

# 2.6.4. THREAT OF SUBSTITUTE PRODUCT

# 2.6.5. INTENSITY OF COMPETITIVE RIVALRY

# 2.7.     KEY BUYING CRITERIA

# 2.7.1. APPLICATION

# 2.7.2. PRICING

# 2.7.3. EFFECTIVENESS

# 2.7.4. AVAILABILITY

# 2.8.     STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS

CHAP# 3.             MARKET DETERMINANTS

# 3.1.     MARKET DRIVERS

# 3.1.1. RISING AGING POPULATION

# 3.1.2. GROWING OSTEOPOROSIS CASES

# 3.1.3. CHANGING DIETARY HABITS

# 3.2.     RESTRAINTS

# 3.2.1. STRINGENT FDA REGULATION

# 3.2.2. PRESENCE OF ALTERNATIVES

# 3.3.     MARKET OPPORTUNITIES

# 3.3.1. UNTAPPED APAC REGION

# 3.3.2. HIGH COST OF IRON BASED HYPERPHOSPHATEMIA DRUG

# 3.4.     MARKET CHALLENGES

# 3.4.1. HIGH COST OF IRON BASED HYPERPHOSPHATEMIA DRUG

CHAP# 4.             SECTOR ANALYSIS

# 4.1.1. PARENT MARKET - METABOLIC DISORDER THERAPEUTIC MARKET

CHAP# 5.             MARKET SEGMENTATION

# 5.1.     GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2014-2023 ($ MILLION)

# 5.1.1. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

# 5.1.2. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

# 5.1.3. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

# 5.1.4. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

# 5.1.5. GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2014-2023 ($ MILLION)

CHAP# 6.             GEOGRAPHIC ANALYSIS

# 6.1.     NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.     REGIONAL ANALYSIS

# 6.2.1.1.              UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.1.2.              MARKET REVENUE

# 6.2.1.3.              CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.1.4.              MARKET REVENUE

# 6.3.     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.4.     REGIONAL ANALYSIS

# 6.4.1.1.              UNITED KINGDOMHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.4.1.2.              MARKET REVENUE

# 6.4.1.3.              FRANCEHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.4.1.4.              MARKET REVENUE

# 6.4.1.5.              GERMANYHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.4.1.6.              MARKET REVENUE

# 6.4.1.7.              SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.4.1.8.              MARKET REVENUE

# 6.5.     ITALY HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

# 6.5.1. MARKET REVENUE

# 6.6.     ROE GLOBAL HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

# 6.6.1. MARKET REVENUE

# 6.7.     ASIA PACIFICHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.8.     REGIONAL ANALYSIS

# 6.8.1.1.              INDIAHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($MILLION)

# 6.8.1.2.              MARKET REVENUE

# 6.8.1.3.              CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.8.1.4.              MARKET REVENUE

# 6.8.1.5.              JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.8.1.6.              MARKET REVENUE

# 6.8.1.7.              AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.8.1.8.              MARKET REVENUE

# 6.8.1.9.              ROAPACHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.8.1.10.           MARKET REVENUE

# 6.1.     REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.     MARKET REVENUE

# 6.2.1. REGIONAL ANALYSIS

# 6.2.2. LATIN AMERICA HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.2.1.              MARKET REVENUE

# 6.2.3. MENA HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.3.1.              MARKET REVENUE

# 6.2.4. AFRICA GLOBAL HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

# 6.2.4.1.              MARKET REVENUE

CHAP# 7.             COMPANY PROFILE

# 7.1.     AMAG PHARMACEUTICALS

# 7.1.1. OVERVIEW

# 7.1.2. PRODUCT PORTFOLIO

# 7.1.3. SCOT ANALYSIS

# 7.1.4. STRATEGIC ANALYSIS

# 7.2.     JOHNSON AND JOHNSON

# 7.2.1. COMPANY OVERVIEW

# 7.2.2. SCOT ANALYSIS

# 7.2.3. STRATEGIC ANALYSIS

# 7.3.     CIPLA

# 7.3.1. OVERVIEW

# 7.3.2. PRODUCT PORTFOLIO

# 7.3.3. SCOT ANALYSIS

# 7.3.4. STRATEGIC ANALYSIS

# 7.4.     KERYX BIOPHARMACEUTICALS

# 7.4.1. OVERVIEW

# 7.4.2. STRATEGIC INITIATIVES

# 7.4.3. SCOT ANALYSIS

# 7.4.4. STRATEGIC ANALYSIS

# 7.5.     DSM

# 7.5.1. OVERVIEW

# 7.5.2. PRODUCT PORTFOLIO

# 7.5.3. SCOT ANALYSIS

# 7.6.     BIOTECH PHARMACAL

# 7.6.1. OVERVIEW

# 7.6.2. STRATEGIC INITIATIVES

# 7.6.3. PRODUCTS PORTFOLIO

# 7.6.4. SCOT ANALYSIS

# 7.7.     SUN PHARM INC

# 7.7.1. OVERVIEW

# 7.7.2. STRATEGIC INITIATIVE

# 7.7.3. SCOT ANALYSIS

# 7.7.4. STRATEGIC ANALYSIS

# 7.8.     ZERIA PHARMACEUTICAL

# 7.8.1. OVERVIEW

# 7.8.2. SCOT ANALYSIS

# 7.8.3. STRATEGIC ANALYSIS

# 7.9.     ULTRAGENYX

# 7.9.1. OVERVIEW

# 7.9.2. SCOT ANALYSIS

# 7.9.3. STRATEGIC ANALYSIS

# 7.10.   BRUNO FARMACEUTICI SPA

# 7.10.1.               OVERVIEW

# 7.10.2.               PRODUCT PORTFOLIO

# 7.10.3.               STRATEGIC INITIATIVES

# 7.10.4.               SCOT ANALYSIS

# 7.11.   FERMENTA BIOTECH LTD

# 7.11.1.               OVERVIEW

# 7.11.2.               PRODUCT PORTFOLIO

# 7.11.3.               SCOT ANALYSIS

# 7.11.4.               STRATEGIC ANALYSIS

# 7.12.   PFIZER INC.

# 7.12.1.               OVERVIEW

# 7.12.2.               PRODUCT PORTFOLIO

# 7.13.   ROCHE DIAGNOSTICS CORPORATION

# 7.13.1.               OVERVIEW

# 7.13.2.               STRATEGIC INITIATIVES

# 7.13.3.               SCOT ANALYSIS

# 7.13.4.               PRODUCT PORTFOLIO

# 7.13.5.               STRATEGIC ANALYSIS

# 7.14.   R.H. MOORE DRUG CO.

# 7.14.1.               OVERVIEW

# 7.14.2.               PRODUCT PORTFOLIO

# 7.14.3.               SCOT

# 7.14.4.               STRATEGIC ANALYSIS

# 7.15.   VIFOR PHARMA

# 7.15.1.               OVERVIEW

# 7.15.2.               PRODUCT PORTFOLIO

# 7.15.3.               SCOT

# 7.15.4.               STRATEGIC ANALYSIS

 

 

 

 

 

 

TABLE LIST

TABLE # 1             GLOBAL HYPERPHOSPHATEMIA DRUG MARKET BY SEGMENTS 2014-2023 ($ MILLION)

TABLE # 2             IRON BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

TABLE # 3             HEALTH EXPENDITURE PER CAPITA INCREASED FROM 2010 TO 2016 ($)

TABLE # 4             DRIVER IMPACT ANALYSIS OF HYPERPHOSPHATEMIA DRUGS MARKET

TABLE # 5             DAILY INTAKE OF PHOSPHOROUS IN HUMAN BODY

TABLE # 6             RESTRAINTS IMPACT ANALYSIS OF HYPERPHOSPHATEMIA DRUGS MARKET

TABLE # 7             HIGH AND LOW PHOSPHOROUS CONTAINING FOODS

TABLE # 8             MARKET OPPORTUNITIES IMPLICATION ON HYPERPHOSPHATEMIA DRUG MARKET

TABLE # 9             MARKET CHALLENGES IMPACT ANALYSIS OF HYPERPHOSPHATEMIA DRUG

TABLE # 10          LIST OF HYPERPHOSPHATEMIA DRUGS AND ITS COST

TABLE # 11          MARKET CHALLENGES IMPACT ANALYSIS OF HYPERPHOSPHATEMIA DRUG

TABLE # 12          LIST OF HYPERPHOSPHATEMIA DRUGS AND ITS COST

TABLE # 13          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2014-2023 ($ MILLION)

TABLE # 14          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

TABLE # 15          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

TABLE # 16          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

TABLE # 17          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

TABLE # 18          GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2014-2023 ($ MILLION)

TABLE # 19          NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

TABLE # 20          EUROPEHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

TABLE # 21          ASIA-PACIFICHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

TABLE # 22          DEMOGRAPHIC PROFILE OF GERIATRIC POPULATION OVER THE XII PLAN PERIOD

TABLE # 23          PER CAPITA CONSUMPTION OF MAJOR DAIRY PRODUCTS (LITRES/KG) IN AUSTRALIA

TABLE # 24          REST OF THE WORLD HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

 

 

FIGURES LIST

FIGURE # 1          GLOBAL HYPERPHOSPHATEMIA DRUG MARKET SHARE BY GEOGRAPHY 2016-2023 (%)

FIGURE # 2          KEY FINDINGS OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE # 3          WORLDWIDE TOTAL PHARMACEUTICAL R&D EXPENDITURE 2014-2020 ($ BILLION)

FIGURE # 4          COST SAVING AMONG DIFFERENT COUNTRIES AS COMPARED TO U.S. COST 2015

FIGURE # 5          TOP 3 EMERGING COUNTRIES 2016-2023 (CAGR %)

FIGURE # 6          TOP REVENUE GENERATING SEGMENT 2016 & 2023 ($ MILLION)

FIGURE # 7          ASIA PACIFIC REVENUE GROWTH 2014-2023 ($ MILLION)

FIGURE # 8          MARKET SHARE OF ANALYSIS OF KEY PLAYERS 2016 (%)

FIGURE # 9          PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET

FIGURE # 10       KEY BUYING CRITERIA: HYPERPHOSPHATEMIA DRUGMARKET

FIGURE # 11       INVESTMENT PREPOSITION ACROSS REGIONS 2016-2023

FIGURE # 12       GLOBAL YOUNG CHILDREN AND AGED PEOPLE POPULATION 2015-2050

FIGURE # 13       DISEASE-WISE PRESENCE OF FEATURES RELATED TO PATIENTS BOTH WITH AND WITHOUT CKD CONDITIONS

FIGURE # 14       GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

FIGURE # 15       GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

FIGURE # 16       GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

FIGURE # 17       GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2014-2023 ($ MILLION)

FIGURE # 18       GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2014-2023 ($ MILLION)

FIGURE # 19       UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 20       AGING POPULATION IN CANADA IN MILLION

FIGURE # 21       CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 22       UKHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 23       FRANCEHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 24       PER CAPITA CONSUMPTION OF MEAT PRODUCTS IN GERMANY IN 2014 AND 2015, BY TYPE (IN KILOGRAMS)

FIGURE # 25       GERMANYHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 26       SPAINHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 27       ITALYHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 28       ROE HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 29       AGE WISE DISTRIBUTION OF INDIAN POPULATION

FIGURE # 30       INDIAHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 31       CHINAHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 32       NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)

FIGURE # 33       JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 34       AUSTRALIAHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 35       ROAPACHYPERPHOSPHATEMIA DRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 36       REST OF THE WORLD GLOBAL HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 37       LATIN AMERICA HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 38       MENA HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

FIGURE # 39       AFRICA GLOBAL HYPERPHOSPHATEMIADRUGS MARKET 2014-2023 ($ MILLION)

 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample
Select License Type
Required More Information

0731 4042636

+91 9713031393

UPCOMING REPORTS

No upcoming reports available under this subcategory.

NAVIGATION LINK

OUR SERVICES

credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: [email protected]

 

 

  • facebook
  • twitter
  • blog
  • linkdin
  • google plus
  • youtube
Go To Top
viewthroughconversion